PF-07275315: A Trispecific Antibody Poised to Redefine the Treatment of Type 2 Inflammation

Executive Summary

PF-07275315 is a first-in-class, investigational trispecific monoclonal antibody being developed by Pfizer as a potential cornerstone therapy for Type 2 inflammatory diseases.[1] Classified as a New Molecular Entity (NME), this biologic therapeutic is engineered with a novel mechanism of action (MoA) that simultaneously targets and inhibits three key cytokines central to the pathophysiology of atopic conditions: Interleukin-4 (

IL−4), Interleukin-13 (IL−13), and Thymic Stromal Lymphopoietin (TSLP).[2] This multi-pronged approach represents a significant evolution from existing biologics, which typically target one or two of these pathways. The strategic rationale is to achieve a more comprehensive and synergistic blockade of the Type 2 inflammatory cascade, targeting both the upstream initiation signal (TSLP) and the key downstream effector cytokines (

IL−4/IL−13) that perpetuate the disease process.[4]

Currently, PF-07275315 is advancing through Phase II of clinical development for two major indications: moderate-to-severe atopic dermatitis (AD) and moderate-to-severe asthma.[1] The clinical program is designed to rigorously evaluate its efficacy and safety in patient populations with significant unmet medical needs, including those who have had an inadequate response to current standards of care.[7]